Phase Ib, Open-label, Multicenter, Dose-escalation Study Followed by an Extension Phase to Evaluate the Safety and Activity of the Combination of Crizotinib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Crizotinib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- 14 Mar 2018 Planned End Date changed from 1 Dec 2016 to 1 Feb 2019.
- 14 Mar 2018 Planned primary completion date changed from 1 Oct 2016 to 1 Feb 2019.
- 22 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.